We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
- Authors
Pollack, Seth M; Li, Yonqing; Blaisdell, Megan J; Farrar, Erik A; Chou, Jeffrey; Hoch, Benjamin L; Loggers, Elizabeth T; Rodler, Eve; Eary, Janet F; Conrad, Ernest U, 3rd; Jones, Robin L; Yee, Cassian
- Abstract
Chondrosarcoma has no proven systemic option in the metastatic setting. The development of a non-cross-resistant strategy, such as cellular immunotherapy using antigen-specific T cells would be highly desirable. NY-ESO-1 and PRAME are members of the Cancer Testis Antigen (CTA) family that have been identified as promising targets for T cell therapy. LAGE-1 is a cancer testis antigen 90% homologous to NY-ESO-1, sharing the 157-165 A*0201 NY-ESO-1 epitope with its transcript variant, LAGE-1s. A number of CTA's have been induced using 5-Aza-2-Deoxycitabine (5-Aza-dC) in other cancers. We sought to evaluate the feasibility of targeting chondrosarcoma tumors using NY-ESO-1/LAGE-1s and PRAME specific T cells using 5-Aza-dC to induce antigen expression.
- Publication
PloS one, 2012, Vol 7, Issue 2, pe32165
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0032165